Testing brentuximab and etoposide for T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding the drugs brentuximab and etoposide to standard chemotherapy improves treatment for people newly diagnosed with T-cell lymphoma. It aims to find a more effective first treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with a type of T-cell lymphoma (a cancer of certain immune cells).
- You do not have any active infections or chronic health problems that are getting worse.
- You are able to get out of bed and take care of yourself most of the day (ECOG performance status 0-2).
- You have not had another cancer in the last 5 years, except for easily treated cancers like some skin cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
This trial tests a new combination of targeted antibody-drug (brentuximab vedotin) plus standard chemotherapy (R-CHP) for people with a specific type of aggressive lymphoma that has a virus (EBV) in the tumor cells. The goal is to see if this combination works better than standard treatment.
This trial tests whether the drug brentuximab vedotin can help prevent lymphoma from coming back after a stem cell transplant. It is for people with a specific type of skin lymphoma called mycosis fungoides.
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
This study looks at how well a combination drug treatment (brentuximab vedotin plus chemotherapy) works for patients with rare T-cell lymphomas in real-world clinical practice in Spain. It focuses on patients receiving this as their first treatment.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.